Table 4.
Toxicity of bispecific antibodies in RRMM.
| Agent Name | CRS | Fever | Neurotoxicity/ICANS | Infusion Related Reactions | Overall Infection | Anemia | Neutropenia |
|---|---|---|---|---|---|---|---|
| Teclistamab [19] | 63% | NR | 3% | NR | 42% | 39% | 55% |
| Teclistamab [20] | 72% | NR | 6% | NR | 63% | 50% | 65% |
| Teclistamab + Daratumumab [21] | 61% | NR | 2% | NR | 63% | 46% | 54% |
| Teclistamab + Daratumumab + Lenalidomide [22] | 81% | 25% | 0 | NR | 75% | NR | 75% |
| Elranatamab [23] | 67% | NR | NR | NR | NR | NR | NR |
| Elranatamab [24] | 58% | 22% | 3% | 24% | 62% | 46% | 43% |
| Elranatamab + Daratumumab [25] |
50% | 21% | 0 | NR | NR | NR | 29% |
| Pavuratamab (AMG-701) [26] | 61% | 25% | 8% | NR | NR | 43% | 23% |
| Pacanalotamab (AMG-420) [27] | 38% | NR | 5% | NR | 33% | NR | NR |
| RO7297089 [28] | NR | NR | NR | 48% | NR | 52% | NR |
| ABBV-383 [29] | 57% | 19% | NR | NR | NR | 29% | 37% |
| REGN5458 [30] | 48% | NR | NR | NR | NR | 37% | 29% |
| WVT078 [31] | 61% | 39% | NR | NR | NR | 24% | 12% |
| Talquetamab [32] | 79% | NR | NR | NR | 57% | 45% | 34% |
| Talquetamab + Daratumumab [33] | 65% | NR | 4% | NR | 50% | 39% | NR |
| RG6234 [34] | C1: 82% C2: 78% |
NR | 9% | NR | C1: 57% C2: 37% |
C1: 14% C2: 5% |
C1: 12% C2: 17% |
| Cevostamab [35] | NR | NR | NR | NR | 13% | NR | NR |
| ISB 1342 [36] | 17% | 8% | NR | 42% | NR | 21% | NR |
NR—not recorded, C1—cohort 1, and C2—cohort 2.